Patent intelligence · US
US 8323662
Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein
Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein
Patent details — US 8323662
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 4, 2012
- Expiration
- Nov 29, 2032
- Applicant
- IMMUNE DESIGN CORP.
- Claims
- 24
- CPC classes
- A61K, A61K2039/5256, A61K2039/5258, A61K39/0011
Quick answer
US 8323662 (Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein) is held by IMMUNE DESIGN CORP.. Status: granted. Granted Dec 4, 2012. Expires Nov 29, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- IMMUNE DESIGN CORP.
- Grant date
- Expiration
- Claims
- 24
- CPC classes
- A61K, A61K2039/5256, A61K2039/5258, A61K39/0011, A61K39/001106, A61K39/001135
More from IMMUNE DESIGN CORP.
Related pharmaceutical patents in our USPTO index.
-
US 12378245
Crystalline forms of an RSK inhibitor
granted -
US 12297243
Methods and compositions for reducing the immunogenicity of chimeric notch receptors
granted -
US 12291058
Dispersions for additive manufacturing comprising discrete carbon nanotubes
granted -
US 12268695
Betulin-containing birch bark extracts and their formulation
granted -
US 12247004
2-amino-N-(amino-oxo-aryl-lambda6-sulfanylidene)acetamide compounds and their therapeutic use
granted -
US 12065498
Methods of making bispecific anti-CD307E and anti-BCMA chimeric antigen receptors and uses of the same
granted -
US 12005194
Configurable oxygen concentrator and related method
granted -
US 11998571
Pharmaceutical composition comprising stem cell-conditioned medium and exosome isolated therefrom as active ingredient for prevention or treatment of ocular disease
granted
Frequently asked questions
What is US patent 8323662?
US 8323662 (Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein) is held by IMMUNE DESIGN CORP.. Status: granted. Granted Dec 4, 2012. Expires Nov 29, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8323662?
IMMUNE DESIGN CORP. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 201 pharmaceutical patents for this assignee.
When does US 8323662 expire?
Our index shows an expiration date of Nov 29, 2032 (6 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.